The Europe cervical cancer diagnostic testing market is expected to grow from US$ 1,368.86 million in 2021 to US$ 1,881.38 million by 2028; it is estimated to grow at a CAGR of 4.6% from 2021 to 2028.
Precancerous changes can delay the disease progression, thus offering an extended time window for its treatment. However, due to a lack of awareness or access to diagnostic services, many cases are detected in the later stages of illness. Human papillomavirus (HPV), typically transmitted through sexual contact, is one of the primary causes of cervical cancer. Out of more than 100 HPV strains reported, 13 are high-risk or carcinogenic strains. The HPV test detects human papillomavirus in cervical cells. The active gene E6 or E7 determines whether an HPV strain is of high or low risk. Other screening methods employed in low-resource areas of several countries include HPV DNA testing and visual inspection. Cervical screening on a regular basis aid in the early detection of cervical cancer, lowering the mortality rate from the disease. According to National Cancer Institute, most women belonging to the age group 21–65 should undergo the Pap test while women from the age group 30–65 should undergo the Pap and HPV tests every three years. In terms of revenue, the HPV test dominates the cervical cancer screening market, and this trend is expected to continue during the forecast period, thereby driving the Europe market growth.In case of COVID-19, Europe is highly affected specially the UK. The epidemic has caused a reduction in various medical procedures such as screening, follow-up, HPV triage tests, invasive diagnostic, and treatment of cervix-related indications. There is a need to create awareness among women about the advantages of early cervical cancer screening. The unwillingness of the patients to take the test is expected to have an undesired impact on the market in the region. However, global players such as Hologic Inc. in November 2021 launched Genius Digital Diagnostics System and are now commercially available in Europe. Thus, such active involvement of the international market players in the regional markets is expected to positively impact the region's market.With the new features and technologies, vendors can attract new customers and expand their footprints in emerging markets. This factor is likely to drive the Europe cervical cancer diagnostic testing market. The Europe cervical cancer diagnostic testing market is expected to grow at a good CAGR during the forecast period.
Europe Cervical Cancer Diagnostic Testing Market Revenue and Forecast to 2028 (US$ Million)
- This FREE sample will include data analysis, ranging from market trends to estimates and forecasts.
Europe Cervical Cancer Diagnostic Testing Market Segmentation
Europe Cervical Cancer Diagnostic Testing Market – By Type
- PAP Testing
- HPV Testing
- Colposcopy
- Cervical Biopsies
- Cystoscopy
- Others
Europe Cervical Cancer Diagnostic Testing Market – By Service Provider
- Diagnostics and Research Laboratories
- Hospitals and Clinics
- Specialty Clinics
- Home Care Services
Europe Cervical Cancer Diagnostic Testing Market, by Country
- Germany
- UK
- France
- Italy
- Spain
- Rest of Europe
Europe Cervical Cancer Diagnostic Testing Market - Companies Mentioned
- Abbott
- BD
- Cooper Companies, Inc.
- DYSIS Medical Inc
- F. Hoffmann-La Roche Ltd.
- Femasys Inc.
- Guided Therapeutics, Inc
- Hologic, Inc.
- QIAGEN
- Quest Diagnostics Incorporated
Europe Cervical Cancer Diagnostic Testing Report Scope
Report Attribute | Details |
---|---|
Market size in 2021 | US$ 1,368.86 Million |
Market Size by 2028 | US$ 1,881.38 Million |
Global CAGR (2021 - 2028) | 4.6% |
Historical Data | 2019-2020 |
Forecast period | 2022-2028 |
Segments Covered |
By Type
|
Regions and Countries Covered | Europe
|
Market leaders and key company profiles |
- Historical Analysis (2 Years), Base Year, Forecast (7 Years) with CAGR
- PEST and SWOT Analysis
- Market Size Value / Volume - Global, Regional, Country
- Industry and Competitive Landscape
- Excel Dataset
Testimonials
Reason to Buy
- Informed Decision-Making
- Understanding Market Dynamics
- Competitive Analysis
- Identifying Emerging Markets
- Customer Insights
- Market Forecasts
- Risk Mitigation
- Boosting Operational Efficiency
- Strategic Planning
- Investment Justification
- Tracking Industry Innovations
- Aligning with Regulatory Trends
Yes! We provide a free sample of the report, which includes Report Scope (Table of Contents), report structure, and selected insights to help you assess the value of the full report. Please click on the "Download Sample" button or contact us to receive your copy.
Absolutely — analyst assistance is part of the package. You can connect with our analyst post-purchase to clarify report insights, methodology or discuss how the findings apply to your business needs.
Once your order is successfully placed, you will receive a confirmation email along with your invoice.
• For published reports: You’ll receive access to the report within 4–6 working hours via a secured email sent to your email.
• For upcoming reports: Your order will be recorded as a pre-booking. Our team will share the estimated release date and keep you informed of any updates. As soon as the report is published, it will be delivered to your registered email.
We offer customization options to align the report with your specific objectives. Whether you need deeper insights into a particular region, industry segment, competitor analysis, or data cut, our research team can tailor the report accordingly. Please share your requirements with us, and we’ll be happy to provide a customized proposal or scope.
The report is available in either PDF format or as an Excel dataset, depending on the license you choose.
The PDF version provides the full analysis and visuals in a ready-to-read format. The Excel dataset includes all underlying data tables for easy manipulation and further analysis.
Please review the license options at checkout or contact us to confirm which formats are included with your purchase.
Our payment process is fully secure and PCI-DSS compliant.
We use trusted and encrypted payment gateways to ensure that all transactions are protected with industry-standard SSL encryption. Your payment details are never stored on our servers and are handled securely by certified third-party processors.
You can make your purchase with confidence, knowing your personal and financial information is safe with us.
Yes, we do offer special pricing for bulk purchases.
If you're interested in purchasing multiple reports, we’re happy to provide a customized bundle offer or volume-based discount tailored to your needs. Please contact our sales team with the list of reports you’re considering, and we’ll share a personalized quote.
Yes, absolutely.
Our team is available to help you make an informed decision. Whether you have questions about the report’s scope, methodology, customization options, or which license suits you best, we’re here to assist. Please reach out to us at sales@theinsightpartners.com, and one of our representatives will get in touch promptly.
Yes, a billing invoice will be automatically generated and sent to your registered email upon successful completion of your purchase.
If you need the invoice in a specific format or require additional details (such as company name, GST, or VAT information), feel free to contact us, and we’ll be happy to assist.
Yes, certainly.
If you encounter any difficulties accessing or receiving your report, our support team is ready to assist you. Simply reach out to us via email or live chat with your order information, and we’ll ensure the issue is resolved quickly so you can access your report without interruption.















- Abbott
- BD
- Cooper Companies, Inc.
- DYSIS Medical Inc
- F. Hoffmann-La Roche Ltd.
- Femasys Inc.
- Guided Therapeutics, Inc
- Hologic, Inc.
- QIAGEN
- Quest Diagnostics Incorporated


